Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
  • Publication number: 20220370442
    Abstract: The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.
    Type: Application
    Filed: July 21, 2022
    Publication date: November 24, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Shinji SATO, Kenji MAEDA, Dai ISHIKAWA, Mai NAKAMURA
  • Patent number: 11504511
    Abstract: A pharmaceutical product including a housing that defines a cavity, wherein the cavity stores a pharmaceutical material, and wherein the housing comprises a material configured to dissolve based on contact with a fluid, an ingestible device to encode information in a current signature, wherein the ingestible device is positioned within the housing, and a protective material that encompasses the ingestible device. The ingestible device may be attached to a flexible component, wherein the flexible component is configured to releasably secure the ingestible device within the housing.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: November 22, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hooman Hafezi, Raymond Schmidt
  • Publication number: 20220363693
    Abstract: A compound of formula (I): wherein Ring A, Q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, a, b, c and d are as defined in the specification.
    Type: Application
    Filed: July 23, 2019
    Publication date: November 17, 2022
    Applicants: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tadashi SHIMAMURA, Ryo KATO, Risako MIURA, Takashi MITA, Takahiro OGAWA, Yufu SAGARA, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Jeffrey David ST. DENIS, John Walter LIEBESCHUETZ
  • Publication number: 20220346664
    Abstract: Methods, devices and systems for acquiring information useful to support a patient in implementing and adhering to a medically prescribed therapy plan are provided. The therapy may incorporate biofeedback methods and/or personalized therapy aspects. A method includes steps of receiving, by a receiving device, biometric information associated with an ingestible event marker; analyzing, by a computing device having a microprocessor configured to perform a biometric information analysis, the biometric information; and determining a therapeutic recommendation at least partly on the basis of the analysis and/or integrating biofeedback techniques into patient therapy or activity. A system includes a biometric information module to receive biometric information associated with an ingestible event marker; an analysis module to analyze the biometric information; and a determination module to optionally determine and communicate a therapeutic recommendation at least partly on the basis of the analysis.
    Type: Application
    Filed: July 14, 2022
    Publication date: November 3, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Marc JENSEN, Robert LEICHNER, Patrick BEAULIEU, Kityee AU-YEUNG, Lawrence ARNE, Mark ZDEBLICK, Andrew THOMPSON, George SAVAGE, Timothy ROBERTSON, Yashar BEHZADI
  • Patent number: 11478473
    Abstract: The present invention provides a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: October 25, 2022
    Assignees: Amino Up Co., Ltd., Otsuka Pharmaceutical Co., Ltd.
    Inventors: Kazunori Goto, Jun Nakahigashi, Atsuya Sato, Yosuke Hirayama, Moeri Horikoshi, Noriyuki Kouda, Syoichiro Inoue, Ikutaro Sato, Manami Kato
  • Publication number: 20220331311
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Application
    Filed: March 7, 2022
    Publication date: October 20, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu INOUE
  • Patent number: 11476952
    Abstract: An apparatus that includes a partial power source including a first material and a second material, the partial power source configured to generate, upon contact with a conducting medium, a potential difference between the first material and the second material to provide power to a control device, and generate, using the first material and the second material, a current flow within the conducting medium, the current flow including information encoded based on a variable conductance between the first material and the second material.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: October 18, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Mark Zdeblick, Andrew Thompson, Aleksandr Pikelny, Timothy L. Robertson, Hooman Hafezi
  • Publication number: 20220323364
    Abstract: Controlled activation identifiers for use in ingestible compositions, such as pharma-informatics enabled compositions, are provided. The identifiers include a controlled activation element that provides for activation of the identifier in response to the presence of a predetermined stimulus at a target site of interest. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.
    Type: Application
    Filed: May 10, 2022
    Publication date: October 13, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hooman Hafezi, Timothy Robertson, Olivier Colliou, Mark Zdeblick
  • Publication number: 20220326234
    Abstract: A detection method uses a reaction vessel including a container including a housing part having a first opening opened at an upper portion and a second opening opened at a side portion, and a side wall member fixed to the container so that a capturing region on a metal film is exposed in the second opening. First, a liquid containing a specimen is provided to the housing part. Next, the liquid in the housing part is stirred to capture, into the capturing region, a substance to be detected in the liquid. Next, the metal film is irradiated with light so that surface plasmon resonance occurs in the metal film, and light emitted from the reaction vessel and having a light amount changing depending on the amount of the substance to be detected captured in the capturing region is detected.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 13, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Eiichi OKAWA, Hideyuki FUJII, Kumiko HOSHI
  • Patent number: 11466016
    Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 11, 2022
    Assignees: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Christopher Norbert Johnson, Ildiko Maria Buck, Gianni Chessari, James Edward Harvey Day, Hideto Fujiwara, Christopher Charles Frederick Hamlett, Steven Douglas Hiscock, Rhian Sara Holvey, Steven Howard, John Walter Liebeschuetz, Nicholas John Palmer, Jeffrey David St Denis, David Geoffrey Twigg, Andrew James Woodhead
  • Patent number: 11464423
    Abstract: Power sources that enable in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body power sources of the invention include a solid support, a first high surface area electrode and a second electrode. Embodiments of the in-power sources are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the power sources of the invention.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: October 11, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hooman Hafezi, Timothy Robertson, Eric Snyder, Brad Cozad
  • Publication number: 20220313602
    Abstract: An object is to provide a tablet manufacturing apparatus capable of supplying an IC chip to a desired position of pharmaceutical powder with a high accuracy and suppressing a positional displacement. The IC chip is supported by a positioning guide with a chip main body in a downward manner, and is held in a state of being positioned above pharmaceutical powder filled in a die hole before compression. The IC chip is supplied by a pusher.
    Type: Application
    Filed: June 15, 2022
    Publication date: October 6, 2022
    Applicants: Otsuka Pharmaceutical Co., Ltd., Omori Machinery Co., LTD.
    Inventors: Etsuhiro MAEDA, Yasutoshi KOHATA
  • Publication number: 20220311474
    Abstract: A system for tracking a product from origin to destination is disclosed. The system includes a probe that comprises two plates, a power source and a processor. The power source is controlled by the processor to produce an oscillating output at the plates. Using the oscillating voltage, the probe interrogates a device through capacitive coupling. The device includes a control unit, a memory unit, and first and second materials physically associated with the device for communication using capacitive coupling. Information associated with the device is transferred from the device to the probe through capacitive coupling between the first and second materials and the first and second plates, respectively.
    Type: Application
    Filed: January 18, 2022
    Publication date: September 29, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Mark J. Zdeblick
  • Publication number: 20220305007
    Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
    Type: Application
    Filed: February 11, 2022
    Publication date: September 29, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU
  • Patent number: 11446317
    Abstract: The present invention further provides a composition for inhibiting purine body absorption, a composition for inhibiting purine nucleotide metabolism, a composition for inhibiting phosphatase, a composition for inhibiting uric acid level elevation, a composition for improving blood pressure, a composition for improving blood glucose level, a composition for improving liver function, a composition for controlling serum iron level, or a composition for promoting calcium absorption, comprising an inositol phosphate or a salt thereof. The present invention further provides a composition comprising an inositol phosphate or a salt thereof, wherein the taste thereof is improved by adding thereto a predetermined amount of calcium lactate.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: September 20, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Ikenaga, Hiroki Noguchi, Chieko Kohashi, Noriyuki Kouda, Ayako Takaishi
  • Publication number: 20220280418
    Abstract: Provided is a means that is capable of preventing initial excessive release of an active ingredient and that allows for sustained release of the active ingredient in a pharmaceutically active amount over a long period of time.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 8, 2022
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Motoyasu YOSHIMURA, Takuya FUJII, Naoki KAMADA, Ryohei TOGASHI, Ryuta AONO, Xinyu WANG
  • Publication number: 20220280061
    Abstract: The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can also measure the conditions of the environment surrounding the system.
    Type: Application
    Filed: December 14, 2021
    Publication date: September 8, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Jeremy FRANK, Peter BJELETICH, Hooman HAFEZI, Robert AZEVEDO, Robert DUCK, Iliya PESIC, Benedict COSTELLO, Eric SNYDER
  • Publication number: 20220273647
    Abstract: Provided is a means that is capable of preventing initial excessive release of an active ingredient and that allows for sustained release of the active ingredient in a pharmaceutically active amount over a long period of time.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 1, 2022
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Motoyasu YOSHIMURA, Takuya FUJII, Naoki KAMADA, Ryohei TOGASHI, Ryuta AONO, Xinyu WANG
  • Publication number: 20220265613
    Abstract: The present invention provides an oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(?O)— wherein Y1 is a group such as —C(?O)—, A1 is a group such as a tower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.
    Type: Application
    Filed: February 24, 2022
    Publication date: August 25, 2022
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Minoru OKADA, Masaya Kato, Norifumi Sato, Tetsuyuki Uno, Hideki Kitagaki, Junpei Haruta, Hidetaka Hiyama, Tomonori Shibata
  • Patent number: 11412770
    Abstract: Provided is a novel gel-like food composition. The gel-like food composition contains 0.1 to 10 wt % of a free branched-chain amino acid, 1 to 12 wt % of a protein, and 104/g to 1014/g of a probiotic.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: August 16, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Keiko Toyooka, Koichiro Hamada, Hiroshi Saitoh